Reproductive health

Boston IVF Welcomes Reproductive Endocrinologist Dr. Sara Arian to Its Growing Fertility Center in Quincy, Massachusetts

Retrieved on: 
Tuesday, November 1, 2022
Sumathi Best Television Presenter Award, Egg, SRI, CEO, Baylor College of Medicine, Knowledge, Clinical research, Reproductive medicine, News, Texas Children's Hospital, Partnership, Research, Degenerative disease, Baylor University, Family, Physician, Reproductive health, IUI, Harvard Medical School, Department, Cleveland, Freezing, Endometriosis, Fertility, IVF, Department of Obstetrics and Gynecology (Massachusetts General Hospital), University, Genetic testing, Houstonia (magazine), ART, Infertility, Assistant, Reproductive biology, Patient, Topical steroid withdrawal, Cleveland Clinic, Pituitary gland, Woman, Society, Female, PCOS, Male, Science, Parent, Polycystic ovary syndrome, Birth control, Medicine, Obstetrics, MD, Master of Science, Gynaecology

WALTHAM, Mass., Nov. 1, 2022 /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, which has assisted in over 125,000 babies born since 1986 and is known for achieving some of the highest IVF success rates in the country, is pleased to announce the addition of fertility doctor, Sara Arian MD, MSci to its national fertility network and local fertility clinic in Quincy, MA.

Key Points: 
  • Boston IVF's Quincy Fertility Center offers physician consultations, intrauterine insemination (IUI) treatments, female and male infertility testing, and more to individuals and couples who wish to build a family through assisted reproductive technologies (ART).
  • Alongside her role as a reproductive endocrinologist, Dr. Arian is also a passionate scientific investigator and researcher.
  • "Boston IVF is truly fortunate to add a talented fertility doctor like Dr. Arian to our growing team of reproductive endocrinologists," said David Stern, CEO of Boston IVF.
  • To learn more about Dr. Arian, to receive fertility treatment advice, or to schedule a consultation, visit http://www.bostonivf.com .

TherapeuticsMD Announces Additional $7 Million Private Placement

Retrieved on: 
Monday, October 31, 2022
Family, Health, Consumer, Women, Baby, Maternity, General Health, Pharmaceutical, Board, U.S. Securities and Exchange Commission, Safety, Annual report, Government, Reproductive health, Woman, Research, Sumathi Best Television Current Reporting Award, Forward-looking statement, Awareness, Director, Terminology, Board of directors, 6th Street, Company, Security (finance), NASDAQ, Perception, COVID-19, Health, Special-purpose acquisition company, Risk management

TherapeuticsMD, Inc. (NASDAQ: TXMD), (TherapeuticsMD or the Company) an innovative, leading womens healthcare company, announced today that it received an additional $7 million private investment in the Companys Series A Preferred Stock from Rubric Capital Management LP.

Key Points: 
  • TherapeuticsMD, Inc. (NASDAQ: TXMD), (TherapeuticsMD or the Company) an innovative, leading womens healthcare company, announced today that it received an additional $7 million private investment in the Companys Series A Preferred Stock from Rubric Capital Management LP.
  • The Company's Board of Directors and management team continue to actively assess strategic alternatives to strengthen the Companys long-term financial position.
  • TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women.
  • To learn more about TherapeuticsMD, please visit https://www.therapeuticsmd.com/ or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Asuragen to Showcase Innovative Diagnostic Lab Solutions at AMP 2022 Conference

Retrieved on: 
Monday, October 31, 2022
AMP, Cystic fibrosis, Virus, CFTR, Genomics, Reproductive health, Adoption, Bio-Techne, Association, Monkeypox, Patient, Diagnosis, IVD, Genetic testing, Software, Asuragen, National Institute, Amplification, Technology, NASDAQ, Genetics, RUO, Severe acute respiratory syndrome coronavirus 2, Workflow, National Institute of Standards and Technology, DNA, Fragile X syndrome, Vaccine, Pharmaceutical industry, Medical imaging, Deletion

MINNEAPOLIS, Oct. 31, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, will present its diagnostic lab solutions at the upcoming annual meeting of the Association for Molecular Pathology (AMP), taking place November 1-5 in Phoenix, Ariz. The company also announced the commercial availability of new molecular controls for monkeypox and other non-variola Orthopoxvirus DNA viruses.

Key Points: 
  • MINNEAPOLIS, Oct. 31, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, will present its diagnostic lab solutions at the upcoming annual meeting of the Association for Molecular Pathology (AMP), taking place November 1-5 in Phoenix, Ariz.
  • At AMP, Asuragen will host two educational workshops, one focused on a streamlined workflow and equitable testing approach for genetic testing and the other on rapid development of molecular controls for emerging diseases.
  • Asuragen provides best-in-class molecular diagnostic products to improve the way patients are treated in genetics and oncology.
  • Our diagnostic tests and companion diagnostic partnerships address current and emerging clinical needs in reproductive health, cancer diagnosis and monitoring and inherited disease.

Fulgent Genetics to Participate in Credit Suisse’s 31st Annual Healthcare Conference

Retrieved on: 
Tuesday, October 25, 2022
Biotechnology, Genetics, Health, Reproductive health, Genetics, Investor relations, Webcast, Conference, NASDAQ, Technology, Degenerative disease, Cloud computing, Company, Battle of Saint-Fulgent, NGS, Health, Genetic testing, Credit, Pharmaceutical industry

Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to participate in Credit Suisses 31st Annual Healthcare Conference on Tuesday, November 8, 2022.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to participate in Credit Suisses 31st Annual Healthcare Conference on Tuesday, November 8, 2022.
  • These representatives of the company will conduct a presentation beginning at approximately 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).
  • A live webcast of the session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com.
  • Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health.

Be The Match BioTherapies® Expands Presence In the San Francisco Bay Area For Allogeneic Therapy Development and Commercialization

Retrieved on: 
Tuesday, October 25, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Reproductive health, National Marrow Donor Program, GMP, Berkeley, Patient, Center for International Blood and Marrow Transplant Research, Research, Graduate School of Management, Collection, Partnership, Senior, University, Onboarding, Economics, Medicine, Center, FDA, NMDP, Solution, List of life sciences, Pharmaceutical industry, Match

Chris McClain, Senior Vice President, will work from the San Francisco area to support an expanding client base seeking high-quality cellular source material for allogeneic therapy development and commercialization to deliver time-critical cell therapies to patients.

Key Points: 
  • Chris McClain, Senior Vice President, will work from the San Francisco area to support an expanding client base seeking high-quality cellular source material for allogeneic therapy development and commercialization to deliver time-critical cell therapies to patients.
  • Since 2016 Be The Match BioTherapies has provided cell sourcing and supply chain management services for the development of allogeneic cell therapies.
  • Chris McClain leads the sales and business development team for Be The Match BioTherapies.
  • Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain.

Inception Fertility Partners with Leading Technology Companies on Breakthrough Studies to Advance Reproductive Medicine

Retrieved on: 
Wednesday, October 26, 2022
Adoption, Fertility clinic, Reproductive health, OTO, Uray Géza, Medicine, IVM, Therapy, Heart rate, Female, Woman, Science, IVF, Education, LLC, Parent, Reproductive medicine, Patient, ART, Research, Bundled payment, Mental health, Inception, Electrophysiology, Partnership, Technology, Temperature, Goal, Oocyte, Doctor of Philosophy, Industry, Health, CEO, Ecosystem, Egg, Fertility, Genetic testing, URA, Infertility, Oura, Oura (company), PGT, Heart, Pregnancy, Menstrual cycle, LOTUS, Fertility preservation, Leadership, Birth control, Agriculture, Medical device, Medical imaging, Mineral oil, Health insurance, Alife

HOUSTON, Oct. 26, 2022 /PRNewswire/ -- Continuing its mission to lead advancements in reproductive science and medicine, Inception Fertility™ (Inception) announced today its clinical research team has partnered with leading technology companies on five fertility studies that will elevate the patient experience, evolve fertility services, and enhance pregnancy outcomes.

Key Points: 
  • North America's largest fertility provider leans into new technologies to help evolve and improve the fertility experience, pregnancy outcomes
    HOUSTON, Oct. 26, 2022 /PRNewswire/ -- Continuing its mission to lead advancements in reproductive science and medicine, Inception Fertility (Inception) announced today its clinical research team has partnered with leading technology companies on five fertility studies that will elevate the patient experience, evolve fertility services, and enhance pregnancy outcomes.
  • "Our partnerships with leading technology companies allow us to keep fertility patients, including their experiences and outcomes, at the center of our mission."
  • OTO and Inception are partnering on a groundbreaking study to investigate what impact stress has on IVF cycle outcomes.
  • Inception Fertility (Inception) is a family of fertility brands committed to helping patients build their own families.

Foria Announces New Executive Team To Lead Brand Growth

Retrieved on: 
Monday, October 24, 2022
Reproductive health, COA, Cannabis, Female, Pleasure, Growth, Thrive Market, Woman, DTC, Education, Saks Fifth Avenue, COO, Plant, Gemma, Budget, Human, Marketing, Health, CEO, Neiman Marcus, Advertising, CMO, Ulta, Management, Dietary supplement, Nordstrom

LOS ANGELES, Oct. 24, 2022  /PRNewswire-PRWeb/ -- This week, Jon Brandon, CEO & Co-Founder of plant-based sexual wellness company Foria, is excited to introduce a new executive team, strategically assembled to fuel the next phase of the company's growth. Foria welcomes Liz Dolinski as Chief Marketing Officer who will work alongside Gemma DePalma (newly promoted to Chief Operating Officer).

Key Points: 
  • The new executive team will lead the brand's next chapter of national and international growth through a dynamic omnichannel strategy that includes both e-commerce and wholesale.
  • Prior to Foria, Liz was Chief Growth Officer at the DTC sleepwear brand Lunya, where she was responsible for all revenue-driving departments.
  • She joined the Foria team in 2019 as Chief Supply Chain Officer, managing and maintaining executive leadership over the full supply chain team.
  • Discussing the new executive team, Jon shared:
    "As Foria evolves into its 'scale-up' phase, I'm genuinely excited to be surrounded by such a talented executive team.

Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

Retrieved on: 
Thursday, October 20, 2022
LinkedIn, Reproductive health, Insemination, SEC, Prevalence, Infertility, Population, Review, Woman, Diagnosis, Annual report, NASDAQ, ART, International Committee for the Nanking Safety Zone, Twitter, Man, Semen, WHO, World, Reproduction, Safety, World Health Organization, Tubing (recreation), GLOBE, Clinical trial, Forward-looking statement, Literature, Royal Australian and New Zealand College of Obstetricians and Gynaecologists, Travel, Terminology, DOI, Male, Pregnancy rate, Risk, Pharmaceutical industry, Birth control

ATLANTA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced an updated study design for its FemaSeed® pivotal trial, which will now focus on couples experiencing male factor infertility. This update reflects a revised strategy to address this underserved population experiencing infertility with a goal of facilitating accelerated enrollment.

Key Points: 
  • This update reflects a revised strategy to address this underserved population experiencing infertility with a goal of facilitating accelerated enrollment.
  • Edward Evantash, M.D., chief medical officer of Femasys, added, As result of the trial redesign, Femasys will be comprehensively evaluating significantly fewer treatment cycles, allowing us to advance our clinical program more efficiently.
  • Most importantly,wehopethis will bring us even closer to being able to provide FemaSeed as an alternative to couples, particularly those struggling with male factor infertility.
  • The FemaSeed LOCAL de novo clinical trial is a prospective multi-center, unblinded study (NCT04968847) requiring evaluation of up to 214 women undergoing 214 FemaSeed cycles due to male factor infertility.

Fulgent Genetics to Announce Third Quarter 2022 Financial Results on Monday November 7, 2022

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, Genetics, Health, Genetic testing, Genetics, NASDAQ, Reproductive health, Cloud computing, Company, Battle of Saint-Fulgent, Technology, NGS, Investor relations, Health, Degenerative disease, Pharmaceutical industry

Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its third quarter 2022 financial results after the market closes on Monday November 7, 2022.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its third quarter 2022 financial results after the market closes on Monday November 7, 2022.
  • Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.
  • The call may be accessed through a live audio webcast on the Investor Relations section of the companys website, http://ir.fulgentgenetics.com .
  • Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health.

Population Services International (PSI) Partners With Babylon to Launch New Digital Service for Low-income Populations in Vietnam

Retrieved on: 
Thursday, October 20, 2022
Health Technology, Artificial Intelligence, Health Insurance, Insurance, Women, Seniors, Health, Public Policy, Government, Professional Services, Men, Philanthropy, Mobile, Wireless, Consumer, Apps, Applications, Healthcare Reform, Foundation, Software, Data Management, Managed Care, Pharmaceutical, Telemedicine, Virtual Medicine, Consumer Electronics, General Health, Technology, Hospitals, NHS, Reproductive health, Trust, Time, Population, Pharmacy, Woman, Self-assessment, Menstruation, NYSE, Social behavior, Intelligence, Income, Hanoi Capital City Special High Command of the People's Army of Vietnam, Research, Telehealth, Partnership, Technology, Population Services International, Medicare, Health, AI, CEO, Awareness, Safety, OI, PSI, Empathy, Health insurance, Medical device, Management, Medicaid

Population Services International (PSI) announced the launch of a new digital health service in Vietnam to help people in low-income communities make informed decisions about their health and efficiently navigate the healthcare system.

Key Points: 
  • Population Services International (PSI) announced the launch of a new digital health service in Vietnam to help people in low-income communities make informed decisions about their health and efficiently navigate the healthcare system.
  • After taking an AI-powered self-assessment with AI OI, an individual is signposted to local health facilities in their area that can provide follow-on services.
  • Our deep global expertise in social behavior change and implementing pathbreaking, consumer-centric technology, uniquely position us to deliver this service, said Karl Hofmann, President and CEO of Population Services International.
  • To this end we are building an integrated digital first primary care service that can manage population health at scale.